TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05733663

Intervention type: DIAGNOSTIC_TEST
Intervention: Endoscopic procedure with duodenal biopsy
Description: * In all patients the investigators will analyse coeliac serology, DQ-genotype, and results of two duodenal biopsy sampling (one at diagnosis before starting the GFD and another sampling during follow-up with GFD) for assessment of both histopathology and intraepithelial lymphocyte subpopulations by T-cell flow cytometry. In addition, clinical, serological, and histological response to GFD will be evaluated.~* T-cell flow cytometry assay is performed as previously described by our group in previous studies. In all patients, an additional duodenal biopsy sample is taken from the second-third portion of the duodenum at the same endoscopic procedure that for histopathology. The normal cut-off values for the IEL cytometric pattern in our laboratory are CD3+TCRγδ+ IEL ≤8.5% (≤mean + 2SD) and CD3- IEL ≥10% (10th percentile). The cut-offs define four intraepithelial lymphogram patterns: normal, isolated decrease in CD3- cells, isolated increase in TCRγδ+ cells, and the coeliac lymphogram.
Study: NCT04253340

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Bone mineral analyser
Description: high resolution digital radiology (200 µm): D0 + M12 Trabecular Bone Score:D0 + M12 DXA scan:D0 + M12
Study: NCT01508988

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-9054
Description: Eye drops 0.3 µg/mL both eyes on Day one

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-9054
Description: Eye drops 1 µg/mL both eyes on Day one

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-9054
Description: Eye drops 3 µg/mL both eyes on Day one

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-9054
Description: Eye drops 10 µg/mL both eyes on Day one

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-9054
Description: Eye drops 20 µg/mL both eyes on Day one

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-9054
Description: Eye drops 30 µg/mL both eyes on Day one

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-9054
Description: Matched-placebo eye drops dosed in the same manner as ONO-9054 in both eyes on Day one
Study: NCT00095979

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ixabepilone
Description: Given IV
Study: NCT03555487

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-choline PET
Description: 5mCi of 18F-FCH will be injected intravenously. PET imaging will be performed on PET/CT scanner. PET/CT from skull base to diaphragm will be started at 50 minutes after the injection.
Study: NCT02485327

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Technosphere Insulin SAR439065 Afrezza®
Description: Pharmaceutical form: dry powder~Route of administration: oral inhalation
Study: NCT01235065

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: type of laryngoscope
Description: Patients who require emergency rapid sequence intubation are randomized to intubation with either the direct laryngoscope or the video laryngoscope

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: type of laryngoscope
Description: Patients who require emergency rapid sequence intubation are randomized to intubation with either the direct laryngoscope or the video laryngoscope
Study: NCT05192265

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antimalarials, pyronaridine-artesunate
Description: The main interventions investigated are pyronaridine-artesunate granules or tablets (Pyramax™) manufactured by Shin Poong Pharmaceuticals, Seoul, Korea. Pyramax granules come in sachets with each containing 60mg of pyronaridine/20mg of artesunate while Pyramax tablets contain 180mg pyronaridine/60mg artesunate.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antimalarials, Artemether + Lumefantrine
Description: Artemether-lumefantrine dispersible tablets (Coartem™, Novartis pharma) twice daily according to body weights. Each dispersible tablet of AL contains 20mg of artemether/120mg of lumefantrine).
Study: NCT00231790

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0634 50 mg
Description: one capsule orally, once daily in morning

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0634 125 mg
Description: one or three capsules orally, once daily in morning

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0634 125 mg
Description: one or three capsules orally, once daily in morning

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for MK-0634
Description: one, two, three or four capsules orally once daily in morning
Study: NCT02643641

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BM32
Description: BM32 is a mixture of 4 different recombinant proteins directed at the major grass pollen allergens, adsorbed on aluminum hydroxide

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BM32
Description: BM32 is a mixture of 4 different recombinant proteins directed at the major grass pollen allergens, adsorbed on aluminum hydroxide

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BM32
Description: BM32 is a mixture of 4 different recombinant proteins directed at the major grass pollen allergens, adsorbed on aluminum hydroxide

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo contains aluminum hydroxide only
Study: NCT04207905

Intervention type: OTHER
Intervention: Healthy Michigan Plan (HMP) coverage with work requirements
Description: For those who are not in the Exempt for Research Purposes group, to be eligible for HMP coverage beginning January 1, 2020, enrollees ages 19-62 must report 80 hours per calendar month of community engagement activities, such as employment, education, job training, job search activities, participation in substance use disorder (SUD) treatment, or community service.
Study: NCT00965133

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Endurance training intervention
Description: High intensive interval training of walking / running on treadmill for 1 1/2 - 4 minute,repeated minimum 4 times, at an intensity equalling at least 80% of maximal heart frequency. Performed 2-5 times per week for 4-8 weeks, totally 24 sessions.
Study: NCT05102318

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulpotomy
Description: Pulpotomy
Study: NCT00059228

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 17beta Estradiol
Description: Alora 100 microgram per day by skin patch for 6 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo skin patch for 6 weeks
Study: NCT02945826

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: One injection of 68Ga-NOTA-AE105
Description: One injection of 68Ga-NOTA-AE105

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET/MRI
Description: Following injection of 68Ga-NOTA-AE105 the patients will be subjected to PET/MRI of the brain
Study: NCT03983200

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rotating Magnetic Therapy
Description: Rotating Magnetic Therapy 30min, bid

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Mecobalamin
Description: mecobalamine 0.5mg,tid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mecobalamin
Description: mecobalamine 0.5mg,tid
Study: NCT01682824

Intervention type: OTHER
Intervention: Nutritional Assessment
Description: Complete dietary intake assessment

Intervention type: OTHER
Intervention: Nutritional Assessment
Description: Complete dietary intake assessment

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Complete TFEQ-R18v2 questionnaire

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Complete TFEQ-R18v2 questionnaire

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Complete EQ-EMA questionnaire

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Complete EQ-EMA questionnaire
Study: NCT02276963

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ublituximab
Description: Monoclonal antibody that specifically binds to the trans-membrane antigen CD20, which induces immune response that causes lysis of B cells.
Study: NCT02766348

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gemcitabine
Description: gemcitabine 1000mg/m2 IV on day 1 an day 8, repeat every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: gemcitabine 1000mg/m2 IV on day 1 an day 8, repeat every 3 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DC-CTL
Description: 8×10\^9 DC-CTL cells for each infusion, IV(In the vein) for 3 cycles, each cycle received four infusions on day 14,16,30 and 32

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatinum
Description: cisplatin 25mg/m2 IV on day 1,2 and 3, repeat every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatinum
Description: cisplatin 25mg/m2 IV on day 1,2 and 3, repeat every 3 weeks.
Study: NCT03049826

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional status
Description: Body composition and nutrient status
Study: NCT02151357

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCBCI0901
Description: DCBCI0901 7.5mg/m2 iv infusion for day 1 to day 5 and day 15 to day 20
Study: NCT01302405

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRI-724
Description: Dose escalation
Study: NCT03745053

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Xlimus DES Implantation during coronary angioplasty
Description: Xlimus DES Implantation during coronary angioplasty

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Synergy DES Implantation during coronary angioplasty
Description: Synergy DES Implantation during coronary angioplasty
Study: NCT00707044

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control group (usual care)
Description: control group, care as usual, 24 hours intensive care stay

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Short-Stay Intensive Care treatment (SSIC)
Description: Short-Stay Intensive Care treatment (SSIC), 8 hours of Intensive care treatment
Study: NCT03787823

Intervention type: PROCEDURE
Group type: OTHER
Intervention: robotic Prostatectomy (RARP)
Description: Modification of robotic Prostatectomy Arm A classic technique/ anterior transperitoneal RARP Arm B Transdouglas Technique/retzius-sparing RARP

Intervention type: PROCEDURE
Group type: OTHER
Intervention: robotic Prostatectomy (RARP)
Description: Modification of robotic Prostatectomy Arm A classic technique/ anterior transperitoneal RARP Arm B Transdouglas Technique/retzius-sparing RARP
Study: NCT03634943

Intervention type: OTHER
Intervention: Patients with Nutritional Support
Description: Evaluation of Enteral Nutrition or Parenteral Nutrition or both administered to the patients needing artificial Nutritional Support
Study: NCT03582384

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocofersolan
Description: After baseline labs are obtained, therapy with tocofersolan will be initiated at an initial dose of 17 mg/kg of d-alpha-tocopherol in the form of tocofersolan (0.34 ml/kg/day) and titrated based on blood levels.
Study: NCT00179140

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nutritional supplementation
Description: oral administration of protein supplement (Nepro) during hemodialysis; every other day, 3 days per week for 6 months; Nepro is a lactose-free formula that contains a total of 960 kilocalories: 132.8 kilocalories from protein, 412.8 kilocalories from carbohydrates, and 412.8 kilocalories from fat

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nutritional supplementation
Description: oral administration of protein supplement (Nepro) during hemodialysis; every other day, 3 days per week for 6 months; Nepro is a lactose-free formula that contains a total of 960 kilocalories: 132.8 kilocalories from protein, 412.8 kilocalories from carbohydrates, and 412.8 kilocalories from fat

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: exercise
Description: either before or during hemodialysis, patients will perform a leg press exercise; every other day, 3 days per week, for 6 months
Study: NCT01576575

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine Control
Description: Control (no pretreatment) - intravenous and sublingual buprenorphine. Some subjects will only undergo session 1 (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine + Rifampin
Description: Liver and gut CYP3A induction (rifampin 600 mg daily), intravenous and sublingual buprenorphine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine + Grapefruit juice
Description: Gut only CYP3A inhibition (grapefruit juice the night before), sublingual buprenorphine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine + Ketoconazole
Description: Liver and gut CYP3A inhibition (ketoconazole 400 mg daily), intravenous and sublingual buprenorphine
Study: NCT02339103

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Warmed IV fluids
Description: 1 Liter of warmed IV fluids at 42 degrees celsius

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Warmed perfusion pads
Description: Neoprene perfusion pads placed on the palms and soles to rewarm through focusing on the arteriovenous anastomoses
Study: NCT03107910

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Stigma and Structural Interventions
Description: Stigma focused counseling to address HIV anticipated stigma and online video chatting for HIV/STI testing will be assessed. Stigma and Structural Interventions

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Stigma and Structural Interventions
Description: Stigma focused counseling to address HIV anticipated stigma and online video chatting for HIV/STI testing will be assessed. Stigma and Structural Interventions

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Health Information Seeking
Description: Seeking and evaluating online health information will be assessed.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Health Information Seeking
Description: Seeking and evaluating online health information will be assessed.
Study: NCT02592447

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapy for Targeted Therapy-related Fatigue (TTF)
Description: Cognitive Behavior Therapy for Targeted Therapy-related Fatigue (CBT-TTF) group will receive cognitive behavior therapy to help manage fatigue via FaceTime on an iPad, which will be provided to participants. Participants will meet with a trained therapist who will outline their therapy plan and will be taught how to use the iPad for upcoming therapy sessions. The sessions will initially be held weekly, but the therapist may schedule sessions at 1-, 2-, or 3-week intervals during the 18 week study period. The final session will be conducted either in-person at Moffitt or via FaceTime.

Intervention type: OTHER
Group type: OTHER
Intervention: Wait-List Control Condition (WLC)
Description: Participants randomized to Wait-List Control Condition will continue to receive care under direction of their Moffitt Cancer Center (MCC) physician. Physicians will be informed by email of patients' participation on the basis of elevated fatigue and their randomization to WLC. Chart review and a patient self-report form will be used at baseline and follow-up assessments to determine what, if any, services or interventions participants received in the preceding 18 weeks that might address fatigue.
Study: NCT04536363

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Analogs, Prostaglandin E1
Description: Analog of PGE1:~Infusion starting dose: 0.05 -0.01 mcg per kilogram of weight per minute in infusion continues, maximum 7 days, until achieving the desired clinical response (increase in PaO2), at that time decrease the infusion rate to the lowest dose possible to keep answer. This can be accomplished by decreasing the dose from 0.1 to 0.05 to 0.025 to 0.01 mcg / kg / min.~If the response to 0.05 mcg / kg / min is inadequate, the dose can be increased to 0.4 mcg / kg / min, although in general high doses do not produce better effects. Maximum continuous infusion for up to 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard therapeutic protocol
Description: Standard medical treatment is governed by current recommendations of national scientific societies and the Ministry of Health and Social Protection and may be modified throughout the course of the study according to the available evidence. In addition, the criteria of the treating physician are taken into account.~Among the alternatives proposed by the current clinical practice guidelines are:~1. Dexamethasone (4mg ampoule, intravenous) Dose: 6mg intravenous every day for a maximum of 10 days~2. Tocilizumab Dose: 8 mg / kg (maximum dose of 800 mg) IV, maximum 3 doses 8 to 12 hours apart~3. Empirical Antibiotic Therapy in patients with suspected pneumonia (according to management guidelines)~4. Enoxaparin (40mg prefilled syringe) Dose: 40mg subcutaneously every 24 hours~5. Enoxaparin (20mg, 40mg, 60mg, 80mg prefilled syringe) Dose: 1mg / kg every 12 hours~6. Low molecular weight heparin (5000IU prefilled syringe) Dose: 5,000 IU subcutaneous every 12 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard therapeutic protocol
Description: Standard medical treatment is governed by current recommendations of national scientific societies and the Ministry of Health and Social Protection and may be modified throughout the course of the study according to the available evidence. In addition, the criteria of the treating physician are taken into account.~Among the alternatives proposed by the current clinical practice guidelines are:~1. Dexamethasone (4mg ampoule, intravenous) Dose: 6mg intravenous every day for a maximum of 10 days~2. Tocilizumab Dose: 8 mg / kg (maximum dose of 800 mg) IV, maximum 3 doses 8 to 12 hours apart~3. Empirical Antibiotic Therapy in patients with suspected pneumonia (according to management guidelines)~4. Enoxaparin (40mg prefilled syringe) Dose: 40mg subcutaneously every 24 hours~5. Enoxaparin (20mg, 40mg, 60mg, 80mg prefilled syringe) Dose: 1mg / kg every 12 hours~6. Low molecular weight heparin (5000IU prefilled syringe) Dose: 5,000 IU subcutaneous every 12 hours
Study: NCT04581434

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure Therapy
Description: Prolonged Exposure Therapy is an individually-delivered treatment for PTSD that includes in vivo exposure to trauma reminders and imaginal exposure to the trauma memory delivered in 90-minute weekly sessions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy
Description: Cognitive Processing Therapy is an individually-delivered treatment for PTSD that focuses on challenging and modifying maladaptive beliefs related to the trauma, with an optional written trauma account during weekly 60-minute sessions

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Present Centered Therapy
Description: Present Centered Therapy is an individually-delivered treatment for PTSD that focuses on current life problems as manifestations of PTSD in weekly 60-minute sessions. It includes psychoeducation and normalization of responses to trauma, problem solving related to current life difficulties and stress identified by patients, and emotional support and validation
Study: NCT03981471

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Exercise
Description: Elderly people with or without fall history receive exercise to improve balance. Exercise interevention will be given 6 months in 2020. Outcomes (incidence of fall and biological tests) between two arms will be compared.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Exercise
Description: Elderly people with or without fall history receive exercise to improve balance. Exercise interevention will be given 6 months in 2020. Outcomes (incidence of fall and biological tests) between two arms will be compared.
Study: NCT00943852

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: losartan potassium
Description: Single dose losartan 100 mg in one of five treatment periods

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: isosorbide mononitrate (ISMN)
Description: Single dose ISMN 60 mg in one of five treatment periods

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: losartan + ISMN
Description: Single dose losartan 100 mg and ISMN 15 mg in one of five treatment periods

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: losartan + ISMN
Description: Single dose losartan 100 mg and ISMN 60 mg in one of five treatment periods

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo
Description: Single dose placebo only in one of five treatment periods
Study: NCT03430180

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naloxone hydrochloride
Description: Naloxone hydrochloride will be dosed at 4mg / dose (one spray of 0.1ml of the 40mg/ml formulation into one nostril) up to four times daily as needed in response to gambling urges with at least 2 hours between each dose (within 24 hours from 6am each day) for 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One spray of 0.1ml of the placebo formulation in one nostril up to four times daily as needed in response to gambling urges with at least 2 hours between each dose (within 24 hours from 6am each day) for 12 weeks.
Study: NCT03881982

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PIMPERNEL Novel Electronic Log: Pain display can be seen
Description: Pain scores are displayed on the screen when the participant presses the corresponding button

Intervention type: OTHER
Group type: OTHER
Intervention: PIMPERNEL Novel Electronic Log: Pain display is hidden
Description: Participants press the buttons to record their pain score but the score is not on display (the screen is turned backwards).
Study: NCT01661608

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Using the EOS for gastric restriction
Study: NCT02897505

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music Workshop
Description: At each music workshop, the study staff will collect participants' pre- and post-session Physiological and Emotional Thermometer Surveys. The pre-session survey will be conducted prior to the start of the music workshop, and the post-session survey will be conducted within 15 minutes after the conclusion of the workshop.
Study: NCT04579783

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Acetonide
Description: Group A: 40mg triamcinolone acetonide (1mL) + 4mL normal saline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dextrose 5% in water
Description: Group B: 5mL 5% dextrose
Study: NCT02742402

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diagnostic imaging
Description: Abdominal ultrasound, followed by abdominal computed tomography when necessary

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Observation
Description: Observation for 6 to 8 hours. After observation period repeated clinical examination and repeated blood test for calculation of Adult Appendicitis Score is done.